MarketMoodz
GT Biopharma Plans 2026 Phase 1 Basket Trial for GTB-5550 TriKE
GT Biopharma has disclosed plans to launch a 2026 Phase 1 basket trial for GTB-5550 TriKE to target solid tumors, following an IND submission to the FDA in December 2025. The program marks the third NK cell engager GT Biopharma aims to move into human studies, and will leverage insights from the ongoing GTB-3650 trial. Investors should look for trial protocol details and early safety signals as regulators and management outline milestones.
Key Takeaways
- GT Biopharma filed a December 2025 FDA IND for GTB-5550 TriKE to treat solid tumors.
- A 2026 Phase 1 basket trial will use a 1a dose-escalation with up to seven levels and 1b expansion across seven metastatic tumor cohorts.
- GTB-3650’s Phase 1 readout in H1 2026 will inform GTB-5550 development.
- Executive Chairman and CEO Michael Breen called the IND a 'tremendous accomplishment' and highlighted GTB-5550 as GT Biopharma’s third NK cell engager.
- GTBP stock rose about 12.9% in premarket trading to around $0.75 after the news.
People Involved
- Michael BreenExecutive Chairman and CEO
Entities Involved
- GT Biopharma Inc (NASDAQ: GTBP)Biotech company developing NK cell engagers
MarketMoodz Analysis
For investors, the 2026 basket trial could broaden the addressable patient population and yield multiple data readouts across tumor types, but early-stage safety signals and enrollment pace will largely determine the stock’s trajectory.
GTB-5550’s design mirrors a broader industry push into multi-tumor NK cell engager programs. GTB-3650’s ongoing Phase 1 readout in H1 2026 will provide early learnings that could de-risk GTB-5550, but execution risk remains high for first-in-human trials.
Caution is warranted on the market-size claim for B7-H3-expressing solid tumors, which lacks disclosed methodology. Investors should monitor FDA interactions, enrollment timelines, and upcoming GTB-3650 readouts and GTB-5550 milestones as key catalysts.
Source: Original Article
Get AI-Powered Market Insights
Stay ahead of market-moving events with our real-time analysis and stock ratings.
Start Your Free Trial